Cargando…
EK1 with dual Q1004E/N1006I mutation: a promising fusion inhibitor for the HR1 domain of SARS-CoV-2
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694780/ https://www.ncbi.nlm.nih.gov/pubmed/34953899 http://dx.doi.org/10.1016/j.jinf.2021.12.022 |
_version_ | 1784619433088516096 |
---|---|
author | Yan, Fangfang Gao, Feng |
author_facet | Yan, Fangfang Gao, Feng |
author_sort | Yan, Fangfang |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-8694780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The British Infection Association. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86947802021-12-23 EK1 with dual Q1004E/N1006I mutation: a promising fusion inhibitor for the HR1 domain of SARS-CoV-2 Yan, Fangfang Gao, Feng J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2022-04 2021-12-22 /pmc/articles/PMC8694780/ /pubmed/34953899 http://dx.doi.org/10.1016/j.jinf.2021.12.022 Text en © 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Letter to the Editor Yan, Fangfang Gao, Feng EK1 with dual Q1004E/N1006I mutation: a promising fusion inhibitor for the HR1 domain of SARS-CoV-2 |
title | EK1 with dual Q1004E/N1006I mutation: a promising fusion inhibitor for the HR1 domain of SARS-CoV-2 |
title_full | EK1 with dual Q1004E/N1006I mutation: a promising fusion inhibitor for the HR1 domain of SARS-CoV-2 |
title_fullStr | EK1 with dual Q1004E/N1006I mutation: a promising fusion inhibitor for the HR1 domain of SARS-CoV-2 |
title_full_unstemmed | EK1 with dual Q1004E/N1006I mutation: a promising fusion inhibitor for the HR1 domain of SARS-CoV-2 |
title_short | EK1 with dual Q1004E/N1006I mutation: a promising fusion inhibitor for the HR1 domain of SARS-CoV-2 |
title_sort | ek1 with dual q1004e/n1006i mutation: a promising fusion inhibitor for the hr1 domain of sars-cov-2 |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694780/ https://www.ncbi.nlm.nih.gov/pubmed/34953899 http://dx.doi.org/10.1016/j.jinf.2021.12.022 |
work_keys_str_mv | AT yanfangfang ek1withdualq1004en1006imutationapromisingfusioninhibitorforthehr1domainofsarscov2 AT gaofeng ek1withdualq1004en1006imutationapromisingfusioninhibitorforthehr1domainofsarscov2 |